<SEC-DOCUMENT>0001144204-14-069781.txt : 20141119
<SEC-HEADER>0001144204-14-069781.hdr.sgml : 20141119
<ACCEPTANCE-DATETIME>20141119163003
ACCESSION NUMBER:		0001144204-14-069781
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20141119
FILED AS OF DATE:		20141119
DATE AS OF CHANGE:		20141119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		141235851

	BUSINESS ADDRESS:	
		STREET 1:		35 AHAD HA'AM ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			65202
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		35 AHAD HA'AM ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			65202
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v394852_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: November 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>BIO BLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">37 Dereh Menachem Begin St., 15th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Tel-Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F &nbsp;<FONT STYLE="font-family: Wingdings">&#120;
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark, whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Yes&nbsp;<FONT STYLE="font-family: Wingdings">&uml;
</FONT>No <FONT STYLE="font-family: Wingdings"></FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &quot;Yes&quot; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): <U>___</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on
Form 6-K of the registrant consists of the press release issued by the registrant on November 19, 2014, entitled &ldquo;Bio Blast
Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3&rdquo; which
is attached hereto as Exhibit 99.1 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No. &#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">99.1</TD><TD>Press Release issued by Bio Blast Pharma Ltd. on November 19, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 63%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Bio Blast Pharma Ltd. </U><BR>
        (Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        By <U>/s/ Dalia Megiddo</U></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Dalia Megiddo</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 19, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v394852_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="image_002.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #18376A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Bio Blast Pharma Receives Orphan Drug
Designation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>From U.S. FDA for Cabaletta for the Treatment
of Spinocerebellar Ataxia Type 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL AVIV, Israel, November 19, 2014</B> &ndash; Bio Blast
Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for
patients with rare and ultra-rare genetic diseases, announced today that it has been granted Orphan Drug Designation by the&nbsp;U.S.
Food &amp; Drug Administration&nbsp;(FDA) for Cabaletta for the treatment of Spinocerebellar Ataxia Type 3 (commonly known as SCA3
and Machado Joseph disease). This is the second indication for which Bio Blast&rsquo;s Cabaletta has received such designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cabaletta is a chemical chaperone that protects against pathological
processes in cells. It has been shown to prevent pathological aggregation of proteins within cells in several diseases associated
with abnormal cellular-protein aggregation. Cabaletta has demonstrated efficacy in preclinical cells and animal models of SCA3
and other PolyA/PolyQ diseases, including Occulopharyngeal Muscular Dystrophy (OPMD) and Spino bulbar cerebellar ataxia (SBMA,
or Kennedy&rsquo;s disease). Bio Blast plans to make clinical progress in each of these indications in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This orphan drug designation lays the foundation for
what we believe are very favorable conditions to continue to pursue our clinical plans and reflects our commitment to those patients
suffering from rare diseases for which there are few or no therapeutic options. It is yet another step on Bio Blast&rsquo;s route
to create and capture value from our research and clinical work,&quot; stated&nbsp;Dalia Megiddo, MD MBA, Chief Executive Officer
of&nbsp;Bio Blast. We currently are conducting a phase 2 clinical trial to test the efficacy of Cabaletta in SCA3 and plan to start
our SCA3 pivotal study in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Orphan Drug Designation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Orphan drug designation is granted by the&nbsp;FDA Office of
Orphan Products Development&nbsp;(OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than
200,000 patients in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity
upon approval of the drug, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical
research trial design assistance and waives the Prescription Drug User Fee Act (PDUFA) filing fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Bio Blast Pharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bio Blast Pharma is a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Founded in 2012, the company is rapidly building a diverse portfolio
of product candidates with the potential to address unmet medical needs for incurable diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Bio Blast platforms are based on deep understanding of the
disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.
For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
press release may contain forward-looking statements within the meaning of the &quot;safe harbor&quot; provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements
when we discuss</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">that our platforms potentially offer solutions for
several diseases that share the same biological pathology and may address an unmet medical need, when we discuss anticipated progress
in our clinical trials and timing thereof and when we discuss creating value from Bio Blast research and clinical work. In addition,
historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research
or trials would not suggest different conclusions or that historic results referred to in this press release would not be interpreted
differently in light of additional research and clinical and preclinical trials results. Because such statements deal with future
events and are based on Bio Blast Pharma Ltd.'s current expectations, they are subject to various risks and uncertainties and actual
results, performance or achievements of Bio Blast Pharma could differ materially from those described in or implied by the statements
in this press release, including those discussed under the heading &quot;Risk Factors&quot; in Bio Blast Pharma's final IPO prospectus
filed with the Securities and Exchange Commission (SEC) and in any subsequent SEC filings. Except as otherwise required by law,
Bio Blast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as
of the date hereof, whether as a result of new information, future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="Description: http:||l2.yimg.com|bt|api|res|1.2|Vu_9Io6cZ7VEWep70Xb4Jw--|YXBwaWQ9eW5ld3M7cT04NQ--|https:||www.globenewswire.com|newsroom|ti?nf=MTQ1IzEwMDkyMTMwIzMyNDU1" STYLE="height: 2px; width: 2px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Investor Contact:<BR>
Michael Rice<BR>
Founding Partner<BR>
LifeSci Advisors, LLC<BR>
mrice@lifesciadvisors.com<BR>
(646) 597-697</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``U`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BHKBXAM
M('GGD"1H,LQ[5P6H>,+S5+TV6EM]FAYW3XRP4=3[4FU%7>PTFW9'H)90<$@'
MZTI(`R>E>6M?21292665N[S-N8GU]JFOO%=]8^&YTEES+,"D+$_-[GZ"O-P^
M;8?$5?94[M][:';5R^M2I^TG9+UU,_QKXSGOK^33]/F*6<9*LRG_`%A[_A65
MX:URZT6\22%R8B?WD>>&%8,%G=7$F8X9'[\"K<0>)]KJ58=B,5Z9PGO]M/'=
M6T<\1RDBAE/M4M<]X*N&N/#4&XY\MB@^@KH:`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/+?'7B-KK4'T^%\6\!P
MV/XF_P#K5@:!=)_:#Q,0&FB9$/\`M'H*PKR2X6[E6X!$P8[P?6JPD<,&!((.
M0145::J0<'LU8J$W"2DNAZUHOAX:G:RS--Y;JVU05W`'W%:'_"!V3R">XF:X
MN,8W2KE0/0+VK"\">+H'G-G?L(II``LA.%<^_H:]*[9KBP.!AAJ/L[:]6NOS
M.K%8J5:IS7TZ+L<+K>B2:99K*EZ712!L(P1]*YO4D%_I\KR`>=;H763OM'45
MM>(M1BN/%KV*R!EDM1LYXW]A5;3-$N=5#Q*I6%_DD8]E[X]^E>55H3HYE3]A
M?EEOJVO/N>A"K&K@I^UM=>5O0ZKP-`T'A6V+#F4F0?0URGB'Q!KUYXV?1=$N
MA$``F#P`W<DUZ3%%':VJ11J!'&F%`]!7C&EZ7>>*_%VJW=I>&T*LS^:/<XQ^
ME?2GAG0>'O%&OVOB]=!U>2.XW-L+)SM/KGTK7674KKXA%8-:A-G$/GM%DYP.
MHV^OO7*>`9$T_P`7W]I=I'/<JDA^U9R5V]<'WJOX7NY(I_$GB)>98(&*$_WF
M/'\J`/5+_P`1Z/ID_DWNHP0RXSL9N:M)J%M<:>UY;SI+!L+!U.17E'A;P]8:
MQH.J:[K4IE?Y@&9L;2!G)_.H/"=[+:>"_$K>8PB6-1%D\;CD<?I0!/IFL>,O
M$/VVXL+^-8K8[F5FV]<G`]>E='X.\8WFJ:+J;ZB%,EE'N\U1C<"#U]^*XC3O
M#5^_@JZUF#4C!'EM\&2H=1[UJZ7J4,/PIU)8X%BE+>2[C^/=T-`&W\,+N^O_
M`.T;N\N9I4!54\QL@=2?Z5UMSXKT&SG:&XU6V21>JELXKRTZA<:'\-K2"W)C
MFU*9V+C@[!QBHO$.@:=H?A&P=OWFJ79$C/GHN.@'IR*`/8AJ^G'3_M_VR'[(
M>?-W?+5:U\3:)?&06VI02&-"[X/11WKSWQ#X=U&7P'H@LH6D2WB+3QIU)/.[
M'?O4_A*?P[J&CZCMTW[+=1VI2<*WWT[D'MTH`U[#XB07WBJ33R8(;%-P6=F_
MUA!X_.NRO+C[/8S3@_<0L#7DWPW\,V&KR75Y>1,X@=?)^;'/)_PKTGQ++Y.B
M2*/XR$K#%5?94)U.R9K0ASU(Q[LQ+>[UV[M);R*<>7'U!.,_A5L:[+=>'+F1
MSMG3";EXSGO5"PL=9N-,6"$JEK+\V2<9!J36+-=)T6"S#;GE?>Q]<"OEZ=3$
MPHNK>7+RN_,]&WMR_>>U*%&510TOS:6[+>YI:%JD$6G+]LO%$KL2`[9..U;Y
M=0F\L-N,YSQ7"ZII<&GZ7:-@_:9>6.?:K.JS3M'8:4K;<QJ7YZD]*[,/F-7#
M4W2JQNXJ-M=6Y;)WZG/5PD*TU.F])-_<NQTAUK30VTWD6<XZU8DO;:(H))T4
MORN3UKB]8T^UM+RVL[8?O,#><Y))-3Z]$USKEM91'&$5![9JWFN(@IJ<$W%Q
M6C>[Z?(E8&E)QY9.S3>O9'5#4K(K(PN8]L9PYSTIKZM8(5#7<0+C*\]:YS7+
M&#2M+2VAR6F?+$GK@51U73(K#3[+`/VB4$N<_I17S3%4N9.$;Q2;U?5[!2P5
M&I9\S]YM+;IU.RDU.RBF$3W48D/1<U9>1(T+NP51SDFN%U?3(;""R5<F>0$R
M$GKTJWK$DM[JEKI2R8C`4'GJ35_VM5ASJI!<RY4DGUELG^I/U&$N5PEH[W]$
M=%_;6F[MOVR+/3K17)W^GVJZ[!86R_+\JL<YR3112Q^.J2G&,(OE=G9L<\+A
MH*+E)JZOT-S5_!VC:U.9[JW*S'J\;;2?KZUGQ?#?P_$,F.9V']Z3C\JZ^BO=
M/+/);NTMK6X>W^Q6I5&X81X)'UK=@\42P:2;2*-S)C:LCON(%1^,+"XTR[;4
M4@-Q82G,@7[T3>OT]JY:;Q!:11DV<$DDN.#+@!3ZX'6OG:N%S2-5QI3O!]6]
ME^?W'M0Q&!E34IPM)=EN9WB6Y==:C*,5E@B1&(ZAAG_&O4/`OB*/6M)\EU1+
MJ#B15&`P[-7C-QYT\SS2L6=SEB>YKH?`%U+:^+;54SB7,;#V->_3IJ$(Q716
M/(G-SDY=W<]KN8WFMI8T?8[J5#>E>=0?"^\M3)]GUQXA)P^Q2-WUP:]*HJR#
MD=(\!6FBZ?>1P3M)>W,9C-RZ\J#Z"G>'_!$&D:/?:?<S?:$O.)"!CC&*ZRB@
M#S-?A?>Q>;:0ZTZ:?*V70`\_49P:W[SP-;-X4&AV,Q@4R"1Y2,ER.N:ZVB@#
MS9/A=<M`MK+KDOV4'/EJIQ^6<5L:CX#@F\-PZ+8W!MX4D\UV8;B[8ZFNQHH`
MX[5_`<.I>&K#3%N-DMBNV.4C@^N:Q7^%<MQ!";C5Y))T^7YAE57L!FO2Z*`.
M-UOPEJUY<QS:?K4ELJPK$8URHP!['O3M#\!6VD:9?6[W+2SWL>R27&-H]J["
MB@#B?"/@BZ\-:I)<-J!E@*E1$H(#9[FNDUC2VU2%(A+Y84Y/&<UI45G6I0K0
M=.:NF73G*G)2CNB&U@%K:Q0*<A%"YK.U;16U2>)S/L2,8VXK7HJ*N&IU:?LI
MKW=-/0<*TX3YXO4Q]5T0ZE+"?.V)&,;<5'J_A\:A+'/%+Y<J`+]0.E;E%95,
MOP]3FYH_%:_RV-(8JK#EY7MM\SG(O"YCO(KEKIG=2&;<.IJVNB?\3LZB\V[G
M(3'2MBBIAEN&AI&/6^[W74<L96EN^EOD9.K:,=4FA8S;%C[8SFFZEHAU&Z@E
M,VU(@!MQUK8HJYX&A4<G*/Q6;^6Q,<35C:SVO;YF/?Z(;[4(;AIL)&`-F/2H
MM4\/&]O5NX)O*DXS^'>MVBIJ9?AZBDI1^)W>KW0X8JK"UGLK'/VOAD6VHQ77
MVDN4.X[AR317045KA\+2PZ<:2LGJ15K3JM.;O8****Z#(:Z+(C(ZAE88((R#
M7&:UX"TMUENK9FMR`6**,J?IZ444`>>7-BD=UY(8D9QG%>C^#?"=EIRIJ>]I
M;AUPNX8"#OBBB@#L:***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
5HHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``"``(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@#__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
